|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66.16 USD | -1.15% |
|
-3.63% | -18.33% |
| 12:33am | US FDA mandates label updates on CAR-T cancer therapies | RE |
| Apr. 17 | UBS Adjusts Gilead Sciences Price Target to $75 From $81, Maintains Neutral Rating | MT |
Oct 15 (Reuters) -
* REMDESIVIR HAS LITTLE EFFECT ON COVID-19 MORTALITY, WHO STUDY SAYS- FT Source : https://on.ft.com/3k3RPjY
| 1st Jan change | Capi. | |
|---|---|---|
| -18.33% | 82.5B | |
| +27.97% | 672B | |
| +23.58% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.96% | 211B | |
| -0.41% | 203B | |
| -10.02% | 194B | |
| -11.81% | 144B |
GILEAD SCIENCES, INC. 
